GENE ONLINE|News &
Opinion
Blog

Multiple Myeloma
64th ASH Annual Meeting and Exposition: Broad Coverage of Clinical, Social, and Nutritional Issues
2023-01-04
Kite And Arcellx Join Forces for Developing Cell Therapy targeting Multiple Myeloma
2022-12-12
Janssen Scores Another Multiple Myeloma FDA Approval with Tecvayli
2022-10-25
Johnson & Johnson’s Multiple Myeloma Treatment Wins Accelerated Approval
2022-08-24
Oncopeptides’ Pepaxti Won EMA Approval for Multiple Myeloma
2022-08-19
Multiple Myeloma Treatment From BMS Proves Superior Life Expectancy After Further Trial
2022-08-10
J&J, Legend’s Cell Therapy Gets FDA Nod
2022-03-01
Cartesian’s Off-the-shelf RNA Therapy for Myeloma Enters Clinical Trials
2022-01-27
Bristol-Myers Squibb’s Abecma Becomes First Approved CAR T-Cell Therapy for Multiple Myeloma in Japan
2022-01-24
Antengene’s XPO1 Inhibitor Receives First-In-Class Approval in China for Multiple Myeloma
2021-12-20
Considering Manufacturing and Commercial Advantages, Poseida Makes Strategic Shift Towards Allogeneic CAR-T Products
2021-11-10
AbbVie to Acquire TeneoOne and Its Lead Multiple Myeloma Drug
2021-06-27
BMS, bluebird’s Multiple Myeloma Drug Becomes First BCMA Targeting CAR-T Therapy to Snag FDA Okay
2021-03-28
Spotlight: Cancer Drug Licensed from Danish Antibody Developer Continues to Reap Benefits for Janssen
2020-09-04
GSK’s anti-BCMA Therapy Notches FDA Approval for Refractory Multiple Myeloma
2020-08-09
1 2
LATEST
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Amgen Faces Class Action Lawsuit for Concealing $10.7 Billion Tax Bill to Manipulate Stock Price
2023-03-16
ImmunoPrecise Antibodies, Libera Bio Ink $155 Million Pact To Deliver Antibodies With Nanotechnology
2023-03-16
Dermavant Eyes Second Vtama Indication with Topline Atopic Dermatitis Results
2023-03-15
Scroll to Top